Calithera Biosciences Inc: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Calithera Biosciences Inc listata cu simbolul US.CALA ==Descriere companie== Calithera Biosciences, Inc. (www.calithera.com) is a clinical-stage biopharmaceutical company. The Company’s is engaged in discovering and development of targeted therapies, which disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. The Company is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfull...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 1: | Linia 1: | ||
Pagina dedicata companiei Calithera Biosciences Inc listata cu simbolul US.CALA | Pagina dedicata companiei [[Calithera Biosciences]] Inc listata cu simbolul US.CALA | ||
==Descriere companie== | ==Descriere companie== | ||
Calithera Biosciences, Inc. (www.calithera.com) is a clinical-stage biopharmaceutical company. The Company’s is engaged in discovering and development of targeted therapies, which disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. The Company is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. The Company’s principal operations are based in South San Francisco, California. It has a range of pipeline of small molecule drug candidates, which target enzymes controlling metabolically critical pathways in tumor cells and immune cells. It has multiple internally discovered clinical stage compounds that are all enzyme inhibitors. The Company is engaged in developing telaglenastat in combination with standard therapies in a select set of solid tumors. Its lead development pathway for telaglenastat is for the treatment of KEAP1 or NRF2 mutated non-small cell lung cancer (NSCLC). | Calithera Biosciences, Inc. (www.calithera.com) is a clinical-stage biopharmaceutical company. The Company’s is engaged in discovering and development of targeted therapies, which disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. The Company is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. The Company’s principal operations are based in South San Francisco, California. It has a range of pipeline of small molecule drug candidates, which target enzymes controlling metabolically critical pathways in tumor cells and immune cells. It has multiple internally discovered clinical stage compounds that are all enzyme inhibitors. The Company is engaged in developing telaglenastat in combination with standard therapies in a [[SELECT|select]] set of solid tumors. Its lead development pathway for telaglenastat is for the treatment of KEAP1 or NRF2 mutated non-small cell lung cancer (NSCLC). | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 29 septembrie 2024 21:04
Pagina dedicata companiei Calithera Biosciences Inc listata cu simbolul US.CALA
Descriere companie[edit | ]
Calithera Biosciences, Inc. (www.calithera.com) is a clinical-stage biopharmaceutical company. The Company’s is engaged in discovering and development of targeted therapies, which disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. The Company is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. The Company’s principal operations are based in South San Francisco, California. It has a range of pipeline of small molecule drug candidates, which target enzymes controlling metabolically critical pathways in tumor cells and immune cells. It has multiple internally discovered clinical stage compounds that are all enzyme inhibitors. The Company is engaged in developing telaglenastat in combination with standard therapies in a select set of solid tumors. Its lead development pathway for telaglenastat is for the treatment of KEAP1 or NRF2 mutated non-small cell lung cancer (NSCLC).
Grafic actiuni companie[edit | ]